Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Cited by (324)

Items 201–300 of 324

1. Extracellular Vesicle Protein Panel Enables Early Lung Cancer Detection in a Large Clinical Cohort
   Linxiao Han, Yuan-Lin Song, Lin Tong, Jia-Yuan Sun, Xiaoju Zhang, Shu-Jing Chen, Ying Li, Zi-Qi Wang, Lei Gao, Qiaoliang Zhu et al. · 2025 · Journal of Extracellular Vesicles
2. Gene Targeting on Point: Targeted Delivery of Tumor Suppressor Gene CHRDL‐1 via Peptide/FA‐Modified Layered Double Hydroxides Partner With JPH203 for Effective Hepatocellular Carcinoma Inhibition
   Zhouyi Sun, Yang Liu, Tangye Zeng, Huali Zuo, Qitao Hu, Zhou Tian, Qianwen Wang, Bo Zhang, Zhe Tang, Weiyu Chen · 2025 · Advanced Functional Materials
3. Liquid biopsy for the management of gastrointestinal cancers
   Zeinab Salehnia, Delsuz Rezaee, Sajad Ehtiati, Mohammad Bakhtiari, Mohammad Amin Khalilzad, Sajad Najafi · 2025 · Clinica Chimica Acta
4. Diagnostic Accuracy of Next Generation Sequencing Panel using Circulating Tumor DNA in Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
   Mariana Mioti Sebastião, Rodrigo Shimabukuro Ho, João Paulo Venezian de Carvalho, Micha Nussbaum · 2020 · Journal of health economics and outcomes research
5. The Novel Prognostic Index Model of Combining Circulating Tumor DNA and PINK-E Predicts the Clinical Outcomes for Newly Diagnosed Extranodal NK/T-cell Lymphoma
   Dezhi Huang, Qiong Li, Xinlei Li, Naya Ma, Yishuo Duan, Lidan Zhu, Jiali Li, Qin Wen, Lei Gao, Cheng Yang et al. · 2022 · HemaSphere
6. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third‐generation TKI outcomes
   Yan Li, Fanshuang Zhang, Pei Yuan, Lei Guo, Ying Jianming, Jie He · 2020 · Thoracic Cancer
7. Performance of the OncomineTM Lung cfDNA Assay for Liquid Biopsy by NGS of NSCLC Patients in Routine Laboratory Practice
   Giuseppa De Luca, Sonia Lastraioli, Romana Conte, Marco Mora, Carlo Genova, Giovanni Rossi, Marco Tagliamento, Simona Coco, Maria Giovanna Dal Bello, Simona Zupo et al. · 2020 · Applied Sciences
8. Detection of mutation profiles and tumor mutation burden of cerebrospinal fluid circulating DNA by a cancer genomic panel sequencing in glioma patients
   Wenlong Guo, Lei Jin, Jianhao Liang, Guo‐Wang Lin, Jiantao Zheng, Dong Zhou, Sheng-quan Zhan, Haitao Sun, Xiaodan Jiang · 2022 · Clinica Chimica Acta
9. Liquid Biopsy as a Diagnostic and Monitoring Tool in Glioblastoma
   Ligia Gabriela Tătăranu · 2025 · Medicina
10. Dynamics of cell-free DNA in predicting response in adult diffuse glioma on chemoradiotherapy
    Adil Husain, Sridhar Mishra, Rahat Hadi, Avnish Sahu, Swati Kumari, Madhup Rastogi, Rohini Khurana, Saumya Shukla, Mohammed Haris Siddiqui, Nuzhat Husain · 2022 · Cancer Genetics
11. Comprehensive Genomic Analysis of Patients With Non–Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan
    Hsin-Yi Wang, Chao‐Chi Ho, Yen‐Ting Lin, Wei‐Yu Liao, Chung‐Yu Chen, Jin‐Yuan Shih, Chong‐Jen Yu · 2024 · JCO Precision Oncology
12. Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non–Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments
    Jon Zugazagoitia, Daniel Rueda, Nuria Carrizo, Ana B. Enguita, David Gómez-Sánchez, Asunción Díaz-Serrano, Elisabeth Jiménez, Antonio Mérida, Rosa Calero, Ricardo García Luján et al. · 2017 · Clinical Lung Cancer
13. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non–Small-cell Lung Cancer in Asia
    Herbert Ho-Fung Loong, Victoria M. Raymond, Yukimasa Shiotsu, Daniel T. T. Chua, Peter M.L. Teo, T. Yung, Stan M Skrzypczak, Richard Burnham Lanman, Tony S.K. Mok · 2018 · Clinical Lung Cancer
14. Circulating tumor DNA and their added value in molecular oncology
    Mathie P.G. Leers · 2019 · Clinical Chemistry and Laboratory Medicine (CCLM)
15. The Validity and Predictive Value of Blood-Based Biomarkers in Prediction of Response in the Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review
    Frederik A. van Delft, Hendrik Koffijberg, Valesca P. Retèl, Michel M. van den Heuvel, Maarten J. IJzerman · 2020 · Cancers
16. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma
    Daniel I. Hoffman, Kalil G. Abdullah, Makayla M. McCoskey, Zev A. Binder, Donald M. O’Rourke, Arati Suvas Desai, MacLean P. Nasrallah, Ashkan Bigdeli, Jennifer J. D. Morrissette, Steven S. Brem et al. · 2019 · Journal of Neuro-Oncology
17. Comparative assessment of NOIR-SS and ddPCR for ctDNA detection of EGFR L858R mutations in advanced L858R-positive lung adenocarcinomas
    Daisuke Akahori, Yusuke Inoue, Naoki Inui, Masato Karayama, Hideki Yasui, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Noriyuki Enomoto et al. · 2021 · Scientific Reports
18. Diagnostic accuracy of circulating free DNA testing for the detection of KRAS mutations in non-small cell lung cancer: A systematic review and meta-analysis
    Maria Palmieri, Elisabetta Zulato, Sissel Gyrid Freim Wahl, Nicolas Marie Guibert, Elisa Frullanti · 2022 · Frontiers in Genetics
19. Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era
    Maria Palmieri, Elisa Frullanti · 2023 · Medical Sciences
20. Liquid Biopsy in Non-Small Cell Lung Cancer (NSCLC)
    Christian Diego Rolfo, Marta Castiglia, Alessandro Perez, Pablo Reclusa, Patrick Pauwels, Laure Sober, Francesco Passiglia, Antonio Dello Russo · 2017 · Current clinical pathology
21. Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy
    Xiaohong Han, Ying Han, Qiaoyun Tan, Yü Huang, Jianliang Yang, Sheng Yang, Xiaohui He, Shengyu Zhou, Yan Song, Jinping Pi et al. · 2019 · Journal of Translational Medicine
22. Enhanced Detection of Novel Low‐Frequency Gene Fusions via High‐Yield Ligation and Multiplexed Enrichment Sequencing
    Yi Wu, Jinxiao Guo, Wenjun Li, Xuehao Xiu, Deepak Thirunavukarasu, Yudong Wang, Kai Wang, Weiyu Chen, David Yu Zhang, Xiurong Yang et al. · 2024 · Angewandte Chemie International Edition
23. Utility of cell-free DNA from bronchial washing fluid in diagnosis and genomic determination for radiology-suspected pulmonary nodules
    Xinyu Zhang, Yaping Xu, Yaping Xu, Yencheng Chao, Qin Hu, Chun Li, Maosong Ye, Xiuli Zhu, Liang Cui, Jing Bai et al. · 2022 · British Journal of Cancer
24. Precision treatment for metastatic non–small cell lung cancer: A conceptual overview
    Tristan Taylor Lee, Jeffrey Melson Clarke, Deepali Jain, Sendhilnathan Ramalingam, Vishal Vashistha · 2021 · Cleveland Clinic Journal of Medicine
25. Recent advances in lung cancer genomics: Application in targeted therapy
    Neha Pathak, Sindhura Durga Chitikela, Prabhat Singh Malik · 2021 · Advances in genetics
26. Pathology Issues in Thoracic Oncology: Histologic Characterization and Tissue/Plasma Genotyping May Resolve Diagnostic Dilemmas
    Ibiayi Dagogo‐Jack, Andreas Nicholas Saltos, Alice Tsang Shaw, Jhanelle E. Gray · 2017 · American Society of Clinical Oncology Educational Book
27. Junction Location Identifier (JuLI)
    Hyun‐Tae Shin, Nayoung K. D. Kim, Jae Won Yun, Boram Lee, Sungkyu Kyung, Ki-Wook Lee, Daeun Ryu, Jin-Ho Kim, Joon Seol Bae, Donghyun Park et al. · 2019 · Journal of Molecular Diagnostics
28. Analytical and clinical validation of a NGS panel in detecting targetable variants from ctDNA of metastatic NSCLC patients
    Feifei Fan, Guozhong Jiang, Juan Lv, Hongmin Wang, Wenjie Li, Chenglin Liu, Yu Zhao, Zhou Zhang, Haiwei Du, Zhihong Zhang et al. · 2024 · Cancer Medicine
29. Clinical Applications of Liquid Biopsy in Non-Small Cell Lung Cancer Patients: Current Status and Recent Advances in Clinical Practice
    Shinhee Park, Jae-Cheol Lee, Chang‐Min Choi · 2021 · Journal of Clinical Medicine
30. Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients
    Óscar Juan, Sanjay Popat · 2016 · Lung Cancer
31. Hypermethylation of Circulating Free DNA in Cutaneous Melanoma
    Russell J. Diefenbach, Jenny Lee, David Chandler, Yinan Wang, Christian Pflueger, Georgina Venetia Long, Richard A. Scolyer, Matteo Salvatore Carlino, Alexander Maxwell Menzies, Richard F. Kefford et al. · 2019 · Applied Sciences
32. Results of liquid biopsy studies by next generation sequencing in patients with advanced stage non-small cell lung cancer: Single center experience from Turkey
    Mahmut Büyükşimşek, Mustafa TOĞUN, Kara I Oguz, Atıl Bişgin, İbrahım Boğa, Mert Tohumcuoğlu, Ali Oğul, Abdullah Evren Yetişir, B. Şahin, Hilmi Erdem Sümbül et al. · 2019 · Balkan Journal of Medical Genetics
33. Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data
    Huijuan Chen, Aiqin Wang, Jing Wang, HE Ze-ming, Yanqiu Mao, Liming Liu · 2020 · Journal of Cancer Research and Clinical Oncology
34. Consistency of genotyping data from simultaneously collected plasma circulating tumor DNA and tumor-DNA in lung cancer patients
    Jiali Zhang, Aoran Dong, Shuzhan Li, Xiubao Ren, Xinwei Zhang · 2020 · Journal of Thoracic Disease
35. Circulating tumour DNA as a promising biomarker for breast cancer diagnosis & treatment monitoring
    Riddhi Ursekar, Rohan Chaubal, Khushboo Gandhi, Elizabeth Talker, Jaya Chitra, Aishwarya Raja, Rushikesh Mukhare, Ankita Singh, Anushree Kadam, Mrudula Madhav et al. · 2025 · The Indian Journal of Medical Research
36. Dissecting Tumor Heterogeneity by Liquid Biopsy—A Comparative Analysis of Post-Mortem Tissue and Pre-Mortem Liquid Biopsies in Solid Neoplasias
    Tatiana Mögele, Kathrin Hildebrand, Aziz Sultan, Sebastian Sommer, Lukas Rentschler, Maria Kling, Irmengard Sax, Matthias Schlesner, Bruno Märkl, Martin Trepel et al. · 2025 · International Journal of Molecular Sciences
37. Chemotherapy response monitoring with DNA methylation-based ctDNA tumor fraction: Evidence from a real-world cohort of patients with advanced common solid malignancies
    Christian Diego Rolfo, Moh'd M. Khushman, Alessandro Russo, Roberto Borea, Bernard Herrman, Jing Wang, Jiemin Liao, Carin R. Espenschied, Sean Gordon, Katie Quinn et al. · 2025 · The Journal of Liquid Biopsy
38. Biopsy on Progression in Patients with EGFR Mutation–Positive Advanced Non-Small-Cell Lung Cancer—A Canadian Experience
    Quincy Siu-Chung Chu, Arun Agha, Natalie Devost, Ryan N. Walton, Soma Ghosh, Ching-Liang Ho · 2020 · Current Oncology
39. Secondary Germline Finding in Liquid Biopsy of a Deceased Patient; Case Report and Review of the Literature
    Maedah Veyseh, Charite Nicolette Ricker, Carin R. Espenschied, Victoria M. Raymond, Anishka D'souza, Afsaneh Barzi · 2018 · Frontiers in Oncology
40. Next-generation sequencing of circulating tumor DNA for metastatic non-small cell lung cancer: a discussion on its implementation in the Brazilian clinical practice
    Luiz Henrique Araujo, Carlos Gil Ferreira, Clarissa Serodio da Rocha Baldotto, Clarissa Mathias, Gilberto de Castro, Renata A. Coudry · 2020 · Future Oncology
41. Analytical and Clinical Validation of the Oncomine Dx Target Test to Assess HER2 Mutation Status in Tumor Tissue Samples From Patients With Non–Small Cell Lung Cancer Treated With Trastuzumab Deruxtecan in the DESTINY-Lung01 and DESTINY-Lung02 Studies
    Zhenhao Qi, Thomas Ha, Wenqin Feng, Maha Karnoub, Kaline Pereira, Ryota Shiga, Egbert Frederik Smit, Yasushi Goto, Adrianus Johannes De Langen, Kōichi Goto et al. · 2024 · Archives of Pathology & Laboratory Medicine
42. Feasibility Analysis of Cell-Free DNA Derived from Plasma of Lung Cancer Patients for Next-Generation Sequencing
    Xueli Jiang, Hui Li, Jingjing Liu, Heping Sun, Linna Zhang, Wenxiu Li, Jie Yao, Ying Cheng · 2020 · Biopreservation and Biobanking
43. Metastatic NSCLCs With Limited Tissues: How to Effectively Identify Driver Alterations to Guide Targeted Therapy in Chinese Patients
    Lin Li, Yan Li, Lei Guo, Yutao Liu, Lin Yang, Jianming Ying · 2021 · JTO Clinical and Research Reports
44. Molecular features of tumor-derived genetic alterations in circulating cell-free DNA in virtue of autopsy analysis
    Hayato Koba, Hideharu Kimura, Taro Yoneda, Takashi Sone, Noriyuki Ohkura, Johsuke Hara, Kazuyoshi Hosomichi, Atsushi Tajima, Kazuo Kasahara · 2021 · Scientific Reports
45. Liquid biopsy: the current state of the issue
    Elizaveta Aleksandrovna Pasechnikova, V. N. Bodnya, Шаров Сергей Викторович, Dmitry Vadimovich Kadomtsev, A. Yu. Georgieva, А. I. Stukan · 2021 · Innovative medicine of Kuban
46. Longitudinal multi-gene panel assessment of circulating tumor DNA revealed tumor burden and molecular characteristics along treatment course of non-small cell lung cancer
    Gloria Y. F. Ho, Tao Wang, Hoi‐Hin Kwok, Rehana Rasul, Rita Peila, María G. Guzmán, Msm Ip, David Chi-Leung Lam · 2020 · Translational Lung Cancer Research
47. Clinical utility of liquid biopsy next-generation sequencing for advanced non-small cell lung cancer in the Netherlands
    Tessa J.J. de Bitter, Maartje J. Geerlings, Leonie I. Kroeze, Daniel T. von Rhein, Milou M. F. Schuurbiers, Janne M. Bibbe, Joyce A. M. G. Smeijers, Hicham Ouchene, Christian Gilissen, Tom G. J. Hofste et al. · 2025 · Scientific Reports
48. Implementing liquid biopsy NGS in stage III/IV NSCLC: clinical utility assessment from a real-world Chinese cohort
    Xinxin Yang, Sihang Gao, Ran Ju, Xiaoyong Ji, Shuzhe Deng, Chenxu Guo, Yunjing Hou, Xiaoxi Pan, Lijiao Lin, Li Qu et al. · 2025 · BMC Cancer
49. Clinical Utility of Combined Tissue and Plasma Next-Generation Sequencing in Patients With Advanced, Treatment-Naïve NSCLC
    Helena Bote, Marco Siringo, Esther Conde, Susana Hernández, Fernando López‐Ríos, Alicia Castelo-Loureiro, Esther García-Lorenzo, Javier Baena, Mercedes Herrera, Ana B. Enguita et al. · 2024 · JTO Clinical and Research Reports
50. Identification of Driver Mutations and Risk Stratification in Lung Adenocarcinoma via Liquid Biopsy
    Gopal P. Pathak, Rashmi Shah, Tony Reiman, Alison Wallace, Michael D. Carter, Stephanie Leann Snow, John Fris, Zhaolin Xu · 2025 · Cancers
51. The Role of Circulating Tumor DNA in Patients Treated with Adjuvant Immune Checkpoint Inhibitors: Clinical Reality or Distant Horizon?
    Michele Maffezzoli, Ria Nagpal, Mohamed Ibrahim Elewaily, Lohitha Pedapati, Justin Samuel, Sebastiano Buti, Umberto Malapelle, Akash Maniam, Giuseppe Luigi Banna · 2025 · Current Oncology Reports
52. Targeted Sequencing of Circulating Cell Free DNA Can Be Used to Monitor Therapeutic Efficacy of Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients
    C. Chiou, Chih-Liang Wang, Ji-Dung Luo, Chien-Ying Liu, How-Wen Ko, Cheng-Ta Yang · 2020 · Cancer Genomics & Proteomics
53. Comprehensive analysis of genomic alterations detected by next‑generation sequencing‑based tissue and circulating tumor DNA assays in Chinese patients with non‑small cell lung cancer
    Hua Yang, Junjie Zhang, Lemeng Zhang, Xiaoping Wen, Yongzhong Luo, Dingquan Yao, Tianli Cheng, Huanqing Cheng, Huina Wang, Feng Lou et al. · 2019 · Oncology Letters
54. Comprehensive genomic analysis of circulating tumor DNA for patients with advanced non-small cell lung cancer
    Delphine Lissa, Ana I. Robles · 2019 · Annals of Translational Medicine
55. Circulating tumor DNA- and cancer tissue-based next-generation sequencing reveals comparable consistency in targeted gene mutations for advanced or metastatic non-small cell lung cancer
    Weijia Huang, Kai Xu, Zhenkun Liu, Yifeng Wang, Z. Jeffrey Chen, Yanyun Gao, Ren‐Wang Peng, Qinghua Zhou · 2024 · Chinese Medical Journal
56. Assessing the Sensitivity of Nested PCR Followed by Direct Sequencing on Exosomal DNA for EGFR Mutation Detection in NSCLC
    Mohammad Mehdi Jahani, Parisa Mashayekhi, Mir Davood Omrani, Adnan Khosravi, Dehghanifard Ali, Sanam Azad-Manjiri, Mahyar Zahraei, Maryam Mabani, Sharareh Seifi, Babak Salimi et al. · 2024 · ̒Ulūm va funūn-i bastah/bandī
57. Utility of Circulating Tumor DNA Assay in Identifying Mutations and Guiding Matched Targeted Therapy in Lung Cancers
    Kun Li, Nana Zhang, Bing Xu, Zichen Liu, Dan Zhao, Yujie Dong, Jing Mu, Haifeng Lin, Guangyu Shan, Sihang Gao et al. · 2024 · Clinical Medicine Insights Oncology
58. The applications of plasma cell-free DNA in cancer detection: Implications in the management of breast cancer patients
    Fumie Igari, Hisashi Tanaka, Armando E. Giuliano · 2022 · Critical Reviews in Oncology/Hematology
59. Targeting Oncogenic Driver Mutations in Lung Cancer
    Matthew H. Lee, Fawzi Abu Rous, Alain Borczuk, Stephen V. Liu, Shirish M. Gadgeel, Balázs Halmos · 2023 · Cambridge University Press eBooks
60. Use of Cabozantinib in a Patient With EGFR -Mutated Non–Small-Cell Lung Cancer Harboring Acquired CCDC6-RET Fusion
    Young Kwang Chae, Pedro Antonio Hermida de Viveiros, Caio Teixeira Heleno, Haris Bilal, Bhoomika Sukhadia, Michael S. Oh, Muhammad Mubbashir Sheikh, Wade Thomas Iams, Lee Chun Park · 2019 · JCO Precision Oncology
61. Sensitivity and optimal clinicopathological features for mutation-targeted liquid biopsy in pN0M0 EGFR-mutant lung adenocarcinoma
    Masaoki Ito, Yoshihiro Miyata, Shoko Hirano, Fumiko Irisuna, Kei Kushitani, Yuichiro Kai, Naoto Kishi, Yasuhiro Tsutani, Yukio Takeshima, Morihito Okada · 2021 · Journal of Cancer Research and Clinical Oncology
62. Targeted next generation sequencing of circulating tumor DNA provides prognostic information for management in breast cancer patients
    Hyoeun Shim, Min Jeong Kwon, In Hae Park, Min Kyeong Kim, Eun‐Hae Cho, Junnam Lee, Seung‐Tae Lee, Sung Hoon Sim, Keun Seok Lee, Yunhee Kim et al. · 2022 · Annals of Translational Medicine
63. Response to Pyrotinib in a Patient with Metastatic Bladder Urothelial Carcinoma Harboring HER2 V842I Mutation: A Case Report
    Suyao Li, Qing Liu, Mengling Liu, Tianshu Liu · 2022 · Cancer Management and Research
64. Impact of preanalytical factors on liquid biopsy in the canine cancer model
    Kate Megquier, Christopher R. Husted, Justin Rhoades, Michelle E. White, Diane P. Genereux, Frances L. Chen, Kan Xiong, Euijin Kwon, Ross Swofford, Corrie Painter et al. · 2026 · Communications Medicine
65. Circulating Tumor DNA Detection for Recurrence Monitoring of Stage I Non‐Small Cell Lung Cancer Treated With Microwave Ablation
    Lin Cheng, Sheng Xu, Yufeng Wang, Shengwei Li, Bin Li, Xiaoguang Li · 2025 · Thoracic Cancer
66. Study on NGS-based molecular profiling of malignant pleural effusion supernatant cfDNA in guiding targeted therapy for non-small cell lung cancer
    Yuan Wang, Shuo Liang, Jia-Meng Zhang, Zi-Han Sun, Weihua Li, Yue Sun, Cong Wang, Xinxiang Chang, Linlin Zhao, Huan Zhao et al. · 2026 · Lung Cancer
67. Interpretable deep learning model of circulating genomics for quantitative survival prediction in advanced non-small cell lung cancer
    Yu Wang, Yi-Tong Li, Ming-Hao Wang, Cheng-Yi Zhang, Ying Jiang, Qi Xu, Yingping Liu, Ye-Xiong Li, Nan Bi, Nan Bi · 2026 · Clinical & Translational Oncology
68. The Current Genomic Approaches for Common Respiratory Diseases
    Min Zhang, Youming Zhang · 2016 · Journal of Investigative Genomics
69. Application of liquid biopsy-based targeted capture sequencing analysis to improve the precision treatment of non-small cell lung cancer by tyrosine kinase inhibitors
    Lei Zhang, John W. Coffin, Kim Formenti, Quincy Siu-Chung Chu, Iyare Izevbaye · 2022 · BMJ Open Respiratory Research
70. Tumor‐liver interface in MRI of liver metastasis enables prediction of EGFR mutation in patients with lung cancer: A proof‐of‐concept study
    Shaoping Hou, Hongbo Wang, Xiaoyu Wang, Huanhuan Chen, Boyu Zhou, Ruiqing Meng, Xianzheng Sha, Shijie Chang, Huan Wang, Wenyan Jiang · 2023 · Medical Physics
71. Detection of KRAS mutation using plasma samples in non-small-cell lung cancer: a systematic review and meta-analysis
    Peiling Cai, B Yang, Jiahui Zhao, Peng Ye, Dongmei Yang · 2023 · Frontiers in Oncology
72. Concordance of ctDNA and tissue mutations in NSCLC: A meta-analysis
    Chengyuan Yu, Yitong Han, Mu Wang, Peiyan Hua, Yan Zhang, Bin Wang · 2023 · Cellular and Molecular Biology
73. A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L)
    Kazushige Wakuda, Hiroyuki Yamaguchi, Hirotsugu Kenmotsu, Minoru Fukuda, Kentaro Ito, Yuko Tsuchiya‐Kawano, Kentaro Tanaka, Taishi Harada, Yuki Nakatani, Satoru Miura et al. · 2023 · JTO Clinical and Research Reports
74. Clinical Utility of Circulating Tumor DNA for Detecting Lung Cancer Mutations by Targeted Next‐Generation Sequencing With Insufficient Tumor Samples
    Yi Sun, Xu Zhang, Xinhua Yang, Jiangjun Ma · 2024 · Journal of Clinical Laboratory Analysis
75. Comprehensive Liquid Biopsy Approaches for the Clinical Management of Lung Cancer Using Multiple Biological Matrices
    Areti D. Strati, Martha Zavridou, Kostas A. Papavassiliou, Athanasios G. Papavassiliou · 2025 · International Journal of Molecular Sciences
76. The contribution of the 20th century discoveries on the circulating DNA as biomarkers for cancer screening
    Gilda Alves, Mariana Chantre-Justino, Lucas Delmonico · 2020 · Anais da Academia Brasileira de Ciências
77. The Role of Liquid Biopsies in Lung Cancer Screening
    Ibiayi Dagogo‐Jack, Lecia Van Dam Sequist, Zofia Piotrowska · 2017 · Seminars in Roentgenology
78. Implementation of clinical sequencing for molecular profiling in patients with advanced cancer
    Tomoya Fukui, Kazuko Sakai, Jiichiro Sasaki, Mikiko Kakegawa, Satoshi Igawa, Hisashi Mitsufuji, Masayuki Takeda, Takayuki Takahama, Kazuhiko Nakagawa, Kazuto Nishio et al. · 2021 · Cancer Biomarkers
79. Ultra-Deep Massive Parallel Sequencing of Plasma Cell-Free DNA Enables Large-Scale Profiling of Driver Mutations in Vietnamese Patients With Advanced Non-Small Cell Lung Cancer
    Le Son Tran, Quynh‐Tho Thi Nguyen, Chu Van Nguyen, Vu-Uyen Tran, Thai-Hoa Thi Nguyen, Ha Thu Le, Mai-Lan Thi Nguyen, Vu Le-Thuong, Lam-Son Pham, Binh Thanh Vo et al. · 2020 · Frontiers in Oncology
80. Evolution and clinical impact of genetic epistasis within EGFR-mutant lung cancers
    Collin Michael Blakely, Thomas B.K. Watkins, Wei Wu, Beatrice Gini, Jacob J. Chabon, Caroline Elizabeth McCoach, Nicholas McGranahan, Gareth A. Wilson, Nicolai J. Birkbak, Victor R. Olivas et al. · 2017 · bioRxiv (Cold Spring Harbor Laboratory)
81. Liquid Biopsy
    Marta Castiglia, Lorena Incorvaia, Valerio Gristina, Umberto Malapelle, Viviana Bazan, Christian Diego Rolfo, Antonio Dello Russo · 2021 · UNIPA Springer series
82. Standardized droplet preamplification method for downstream circulating cell-free DNA analysis
    Colin Skeen, Erica D. Pratt · 2025 · BioTechniques
83. Potential supplementary tumor markers for liquid biopsy in non-small cell lung cancer
    Jin Xiang, Junyan Peng, Zhifang Xing, Guoqiang Ren, Huating Zhang, Xiaodong Song, Bo Zhang, Ming Guan, Guojun Cao · 2025 · Experimental Biology and Medicine
84. Updates in Advanced Hormone Receptor-Positive Breast Cancer: From Circulating Tumor DNA-Guided Therapy to Precision Medicine
    Christos Evangelou · 2025
85. Deep learning on brain metastasis for predicting EGFR genotype and EGFR-TKI therapy response in metastatic NSCLC: a multicenter study
    Shuailin You, Ying Fan, Zhiguang Yang, Chunna Yang, Yiyao Sun, Yahong Luo, Zekun Wang, Bo Sun, Wenyan Jiang · 2025 · Frontiers in Bioengineering and Biotechnology
86. A cost-effectiveness analysis model of actionable genomic alteration testing strategies incorporating different modalities and sizes of next-generation sequencing panels in non-small-cell lung cancer
    Y. Ang, J. C. Ong, Yi-Qing Huang, J. Low, K. Sooi, Jorn Nützinger, Xiao-Jun Wang, M. Gibbs, Bo-On C. Goh, R. A. Soo · 2025 · Therapeutic Advances in Medical Oncology
87. Evaluating the Utility and Implementation Barriers of a Liquid Biopsy Biomarker Test Early in the Lung Cancer Diagnostic Pathway to Improve Timeliness of Palliative Systemic Therapy
    Adi Kartolo, Laura Semenuk, Harriet E. Feilotter, Colleen A Savage, Alexander H. Boag, Wilma Hopman, Geneviève C. Digby, Mihaela Mates · 2026 · Current Oncology
88. Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non–Small Cell Lung Cancer
    Michael R. Conroy, Jaime Wehr, Vivian Valeria Altiery De Jesus, Archana Balan, William Bowers, Jennifer W. Li, Susan Combs Scott, Benjamin Philip Levy, Kristen Ashley Marrone, Vincent K. L. Lam et al. · 2026 · Cancer Research Communications
89. Genetic Biomarkers and Their Applications to Prevent Occupational Diseases: A Literature Review
    Kyung-Taek Rim · 2018 · Toxicology and Environmental Health Sciences
90. Secondary Screening for Inherited Pancreatic Ductal Adenocarcinoma
    Andrea Sheel, James Nicholson, Ioannis Sarantitis, John P. Neoptolemos, William Greenhalf · 2018 · Springer eBooks
91. Partitioning for Easy Multiplexing
    Alexia Kinoo, Aurélie Caye‐Eude, Yoann Vial, Hélène Cavé, Chloé Arfeuille · 2023 · Journal of Molecular Diagnostics
92. Enhanced Detection of Novel Low‐Frequency Gene Fusions via High‐Yield Ligation and Multiplexed Enrichment Sequencing
    Yi Wu, Jinxiao Guo, Wenjun Li, Xuehao Xiu, Deepak Thirunavukarasu, Yudong Wang, Kai Wang, Weiyu Chen, David Yu Zhang, Xiurong Yang et al. · 2024 · Angewandte Chemie
93. Lung cancer
    James M. Isaacs, Jeffrey Melson Clarke · 2022 · Elsevier eBooks
94. The Liquid Biopsy, What is it, How is it Provided, and What is the Role of the Pulmonologist
    Sam Durrett, Mark Bowling, Aundrea L. Oliver · 2018 · Clinical Pulmonary Medicine
95. Computational Analysis of DNA and RNA Sequencing Data Obtained from Liquid Biopsies
    Francesco Marass, Francesc Castro-Giner, Barbara Maria Szczerba, Katharina Jahn, Jack Kuipers, Nicola Aceto, Niko Beerenwinkel · 2019 · Recent results in cancer research/Recent Results in Cancer Research
96. A Case of Lung Adenocarcinoma Harboring EGFR Exon19 Deletion/Insertion Mutation Detected by Next-Generation Sequencing (NGS), but Not by PCR
    Kazuhiro Nishiyama, Naoki Furuya, Hajime Tsuruoka, Shinya Azagami, Kazutaka Kakinuma, Takeo Inoue, Akira Endou, Masamichi Mineshita, Noriko Motoi · 2021 · Haigan
97. Circulating tumor DNA use in a community oncology practice
    Erin D. Chamberlain, Carrie L. Costantini, Marin Feldman Xavier · 2019 · Translational Cancer Research
98. Circulating Nucleic Acids as Promising Biomarkers: A New Frontier of Personalized Medicine
    Carolyn Skotz, Samrat Thapa, Mary Nowak, Hoc Lan Phung, Akshitha Mamidi, Hetu Patel, Mabel Ho · 2021 · Berkeley Pharma Tech Journal of Medicine
99. Circulating-tumor DNA from Two Types of Blood Collection Tubes for Monitoring Tumor Burden Validated with Esophageal Squamous Cell Carcinoma Patients
    Fumitaka Endo, Takeshi Iwaya, Yasushi Sasaki, Takehiro Chiba, Mizunori Yaegashi, Kohei Kume, Kei A. Sato, Atsuhiro Arisue, Ryoko Kawagishi, Teppei Matuo et al. · 2020 · medRxiv
100. Secondary Screening for Inherited Pancreatic Ductal Adenocarcinoma
     Andrea Sheel, James Nicholson, Ioannis Sarantitis, John P. Neoptolemos, William Greenhalf · 2017 · Springer eBooks